In NEJM data across 691 adults, the 9 mg dose cut about 34 events per hour in people without diabetes versus about 10 on placebo, alongside up to 22% weight loss.
Recap by typeshit. Full story at EMJ.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
A brief Facebook post says a daily pill might help people who worry about putting weight back on once they come off Wegovy. It names no drug or study.
The author says they found no flaw in retatrutide's phase 3 numbers and argues the strength of the results is itself the problem. The full reasoning is cut off.
Loading…